GW Licenses U.S. Sativex Rights To Otsuka In $273 Million Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms plan to enter a longer-term collaboration later this year to discover novel cannabinoids for use in pain and central nervous system disorders.